NCT04303364进行中（未招募）不适用
CARdiomyopathy in Type 2 DIAbetes Mellitus
Institut National de la Santé Et de la Recherche Médicale, France34 个研究点 分布在 5 个国家目标入组 1,256 人开始时间: 2020年10月2日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,256
- 试验地点
- 34
- 主要终点
- Assess the uniqueness of diabetic cardiomyopathy (DCM) relative to other forms of cardiomyopathy
研究概览
简要总结
The objective of the CARDIATEAM clinical study is to assess the uniqueness of diabetic cardiomyopathy (DCM) relative to other forms of cardiomyopathy using unsupervised clustering approaches based on deep phenotyping (clinical, imaging and biological) information.
详细描述
CARDIATEAM study will address the uniqueness of DCM, and its progression towards heart failure (HF) with preserved ejection fraction (HFpEF) by recruiting a prospective CARDIATEAM cohort (n=1600 individuals) from existing cohorts using a defined set of selection criteria and will include type2-Diabetes mellitus (T2DM)and non-diabetic patients with a large spectrum of demographic, metabolic and cardiac clinical data. This will yield a wide range of T2DM - related phenotypes including common confounders such as BMI, smoking, age and blood pressure.
To clarify the phenotype of DCM and to differentiate it from the other forms of HF such as HFpEF or HCM, CARDIATEAM will perform unbiased clustering analysis from an in-depth phenotyping of these patients' populations
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 40 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Female or male, aged between ≥ 40 and ≤80 years
- •Normal LVEF AND absence of akinetic segment assessed by echocardiography (i.e. LVEF≥50%)
- •Patients diagnosed according to the specific diagnostic criteria of each disease (Cf. table below (definition criteria)). For each group, the diagnosis will be based on current accepted criteria:
- •HFpEF: left ventricular ejection fraction (LVEF) LVEF≥50% AND presence/or history of symptoms (e.g. breathlessness, ankle swelling and fatigue) or signs (e.g. elevated jugular venous pressure, pulmonary crackles and peripheral oedema) of heart failure AND significant diastolic dysfunction (left atrial volume index >34 mL/m2 or a LVMI ≥115 g/m2 for males and ≥95 g/m2 for female, E/e' ≥13 and e' <9 cm/s) OR NT-proBNP >125 pg/Ml
- •No HFpEF: LVEF≥50% AND absence of symptoms (e.g. breathlessness, ankle swelling and fatigue) or signs (e.g. elevated jugular venous pressure, pulmonary crackles and peripheral oedema) of heart failure
- •T2DM: HbA1c ≥ 6.5% (≥ 48 mmol/L) AND Fasting Plasma Glucose ≥7.0 mmol/L (≥126 mg/dL) or anti-diabetic treatment
- •Non T2DM: HbA1c < 6.5% AND Fasting Plasma Glucose <7.0 mmol/L without any anti-diabetic treatment including normoglycemic subjects
- •HCM: patients with non-obstructive HCM of sarcomeric cause (proven with common genetic cause) and with LV wall thickness ≥ 15 mm in one or more myocardial segments in the absence of abnormal afterload conditions.
- •Suitable echocardiographic window
- •Absence of history of coronary artery disease including history of myocardial ischaemia, myocardial infarction or percutaneous coronary intervention
- •Absence of significant coronary artery disease (CAD) defined as:
- •the absence of coronary artery stenosis ≥50% on a cardiac computed tomography (CT) OR a coronary angiography OR normal Fractional Flow Reserve (FFR >0.80) OR
- •Coronary Artery Calcium score (CAC) <100 performed within the 48 months before inclusion
- •Patient covered by a health insurance
- •Non-inclusion criteria:
- •Diabetes mellitus other than type 2 (type 1, LADA, MODY, NODAT, etc.)
- •Suboptimal echocardiographic window
- •Significant valvular heart disease defined as severe aortic regurgitation or severe primary mitral regurgitation or aortic stenosis with a peak transvalvular velocity ≥3m/s or mitral stenosis with a mitral valve area < 1.5cm²
- •Chronic atrial fibrillation or any significant arrhythmia at inclusion
- •Renal insufficiency defined as eGFR<30 mL/min/1.73m²
- •History of and candidate to bariatric surgery
- •Obstructive hypertrophic cardiomyopathy (definition: maximal gradient at rest <30 mmHg)
- •Hypertrophic cardiomyopathy due to a non-sarcomeric etiology, i.e. known infiltrative or storage disorder mimicking HCM such as Fabry disease or amyloidosis
- •Life threatening comorbidities (i.e. history of or active cancer treated with chemotherapy or radiotherapy, end-stage heart failure, severe lung disease, cirrhosis)
- •Pregnancy/Lactating mother
- •Any condition which in the Investigator's opinion makes it undesirable for the subject to participate in the study or which would jeopardize compliance with the protocol
- •Inability to understand the local language
- •Individuals deprived of liberty
- •Protected persons (under guardianship or curatorship)
- •Contra-indication to CMR (please see CMR-SOP):
- •Known hypersensitivity to gadolinium based product (including gadoteric acid and meglumine)
- •Known COVID-19 symptomatic infection requiring hospitalization
排除标准
- 未提供
研究组 & 干预措施
Patients without T2DM and with hypertrophic cardiomyopathy
Patients with T2DM and with hypertrophic cardiomyopathy
Subjects without T2DM and without HF
Patients without T2DM and with HFpEF
Patients with T2DM and without HFpEF
Patients with T2DM and HFpEF
结局指标
主要结局
Assess the uniqueness of diabetic cardiomyopathy (DCM) relative to other forms of cardiomyopathy
时间窗: 3 years
Use of unsupervised clustering approaches based on deep phenotyping (clinical, imaging and biological) information
次要结局
- Identify the best clinical, biological, imaging and multi-OMICs predictors belonging to each identified cluster(4 years)
- Assess prospective health outcomes (i.e. overall mortality, cardiovascular events and cardiac function) in the diabetic cardiomyopathy cluster identified(5 years)
- Explore the pathophysiological and potentially causal pathways characterizing diabetic cardiomyopathy(5 years)
研究者
研究点 (34)
Loading locations...
相似试验
已完成
4 期
Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM)Type 2 DiabetesCoronary Heart DiseaseNCT01588470The University of Texas Health Science Center at San Antonio130
招募中
不适用
CARdiomyopathy in type 2 DIAbetes mellitusDiabetic cardiomyopathyheart failure induced by diabetes1001928010012653NL-OMON52382Medisch Universitair Ziekenhuis Maastricht100
Enrolling By Invitation
不适用
CMR in T2DM: The NSR CohortDiabetic CardiomyopathiesCardiovascular Magnetic Resonance ImagingCoronary Microvascular DysfunctionDiabetes Mellitus, Type 2Fibrosis MyocardiumNCT05915260Slagelse Hospital700
尚未招募
不适用
A Multicenter Clinical Study of Echocardiographic Assessment of Right Heart Function and Implications of Prognosis in DiabetesPrognosisDiabetesNCT04964713Xie Mingxing2,300
招募中
不适用
BIO-2-HEART: Identification of Biomarkers in T2DM and Heart FailureHeart FailureDiabetes Mellitus, Type 2NCT03323216RWTH Aachen University400